Cocrystal Pharma doses last patient in Phase 1b norovirus challenge trial of CDI-988

• Cocrystal Pharma dosed the last participant in a Phase 1b human challenge trial of oral norovirus candidate CDI-988.
• No serious adverse events reported so far, supporting continued clinical development following earlier Phase 1 safety results.
• Study tests CDI-988 for prevention and treatment, aiming to reduce illness from norovirus versus placebo.
• Preliminary efficacy results are expected in late 2026 or early 2027; no efficacy findings have been presented yet.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090700PRIMZONEFULLFEED9823416) on September 09, 2026, and is solely responsible for the information contained therein.